ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0824

Defining Poor Global Functioning and Health in Axial Spondyloarthritis, Using the EQ-5D-3L Questionnaire, When the ASAS-Health Index Is Not Available Is Feasible. an Analysis of 2651 Patients from the PERSPA Study
Abstract Number: 1407

Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA
Abstract Number: 2480

Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI
Abstract Number: 2427

Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis
Abstract Number: 1355

Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Abstract Number: 2082

Delivery of Rheumatology Education to Internal Medicine Residents in Rwanda: Evaluation of a New Virtual Rheumatology Course Supplemented by On-site Clinical Teaching
Abstract Number: 1373

Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome
Abstract Number: 1480

Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region
Abstract Number: 1848

Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease
Abstract Number: 0192

Demographic and Clinical Factors That Contribute to Clinical Study Enrollment in Systemic Lupus Erythematosus
Abstract Number: 0611

Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis
Abstract Number: 1784

Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model
Abstract Number: 1263

Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases
Abstract Number: 1837

Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia
Abstract Number: 0122

Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].